Literature DB >> 10203348

Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease.

S Lincoln1, J Vaughan, N Wood, M Baker, J Adamson, K Gwinn-Hardy, T Lynch, J Hardy, M Farrer.   

Abstract

A coding substitution (I93M) in the ubiquitin carboxy-terminal L1 (UCH-L1) gene has recently been identified in a German family with Parkinson's disease. We have sequenced the entire coding region of the gene in 11 families who have a pattern of disease consistent with autosomal dominant inheritance. We found a polymorphism (S18Y) in exon 3, two polymorphisms in the 5' non-coding region, upstream of the transcription start, and an insertion/deletion polymorphism in intron 4. The S18Y allele is present on approximately 20% of chromosomes in a Caucasian population. These changes are, therefore, unlikely to be pathogenic. We conclude that the I93M variant must either be a rare cause of disease or a harmless substitution whose occurrence in the family reflects a chance co-occurrence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203348     DOI: 10.1097/00001756-199902050-00040

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  30 in total

Review 1.  The genetic basis of Parkinson's disease.

Authors:  T Foltynie; S Sawcer; C Brayne; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

2.  Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury.

Authors:  Linda Papa; Linnet Akinyi; Ming Cheng Liu; Jose A Pineda; Joseph J Tepas; Monika W Oli; Wenrong Zheng; Gillian Robinson; Steven A Robicsek; Andrea Gabrielli; Shelley C Heaton; H Julia Hannay; Jason A Demery; Gretchen M Brophy; Joe Layon; Claudia S Robertson; Ronald L Hayes; Kevin K W Wang
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

3.  Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury.

Authors:  Stefania Mondello; Akinyi Linnet; Andras Buki; Steven Robicsek; Andrea Gabrielli; Joseph Tepas; Linda Papa; Gretchen M Brophy; Frank Tortella; Ronald L Hayes; Kevin K Wang
Journal:  Neurosurgery       Date:  2012-03       Impact factor: 4.654

4.  Porcine UCHL1: genomic organization, chromosome localization and expression analysis.

Authors:  Knud Larsen; Lone Bruhn Madsen; Christian Bendixen
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

Review 5.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 6.  The genetics of Parkinson's disease.

Authors:  Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.

Authors:  James F Burrows; Alyson A Kelvin; Cheryl McFarlane; Roberta E Burden; Michael J McGrattan; Michelle De la Vega; Ureshnie Govender; Derek J Quinn; Karim Dib; Massimo Gadina; Christopher J Scott; James A Johnston
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

9.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

Review 10.  Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis.

Authors:  Margaret Ragland; Carolyn Hutter; Cyrus Zabetian; Karen Edwards
Journal:  Am J Epidemiol       Date:  2009-10-28       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.